Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab.

导出 LinkOut

翻译打印收藏纠错

作者： Mark,Gudesblatt ^[1] ; Myassar,Zarif ^[1] ; Barbara,Bumstead ^[1] ; Marijean,Buhse ^[1] ; Olivia,Kaczmarek ^[1] ; Hanyue,Li ^[2] ; Zhaonan,Sun ^[2] ; Nicole,Scott ^[2] ; Jason P,Mendoza ^[2] ; Robin L,Avila ^[2]

作者单位： NYU Langone South Shore Neurologic Associates, PC, Patchogue, NY, USA. ^[1] Biogen, Cambridge, MA, USA. ^[2]

关键词 COVID-19 Multiple sclerosis natalizumab vaccine

DOI 10.1177/20552173231218117

PMID 38089563

发布时间 2023-12-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Multiple sclerosis journal - experimental, translational and clinical

20552173231218117页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab.

Multiple sclerosis journal - experimental, translational and clinical

相似文献

Multiple sclerosis journal - experimental, translational and clinical

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab.

Multiple sclerosis journal - experimental, translational and clinical

相似文献

Multiple sclerosis journal - experimental, translational and clinical

相关期刊

检索历史清除